Smart Communications Announces Acquisition of Joisto
Smart CommunicationsTM, the leading cloud-based platform for enterprise customer communications, today announces it has acquired Joisto, a cloud data archive company. As a result, customers will now have the ability to seamlessly store, manage and retrieve digital records and documents, while meeting the stringent requirements for data retention that govern regulated industries worldwide.
“We’re delighted to incorporate Joisto’s deep expertise in cloud archival into Smart Communications,” said Leigh Segall, CEO of Smart Communications. “Our leading Conversation Cloud Platform already enables our customers to manage sophisticated customer conversations at tremendous scale. With the addition of Joisto, we will extend these capabilities to meet an increasing need for regulatory-compliant and readily accessible storage of these conversations in the cloud. Together we will support customers worldwide as they continue their journey to modernize and transform customer conversations.”
Joisto’s cloud-based archive solution is built to seamlessly connect to a wide range of core solutions across corporate ecosystems using a comprehensive set of APIs. This enables customers to store, manage, and retrieve documents, irrespective of their source. With powerful data-ingestion capabilities and a modern, scalable, cloud architecture, Joisto easily meets customer requirements to store large volumes of documents, while enabling access from any location. Built with industry regulations and retention rules in mind, Joisto supports compliance with GDPR while driving enhanced document integrity, document authorization and user validation.
“Joisto is thrilled to join forces with Smart Communications,” commented Joisto CEO, Tommi Hänninen. “We deeply understand the importance of archival in regulated industries and we are especially proud to partner with an organization that is equally passionate about providing industry-leading capabilities through a modern, cloud-based architecture. The combination of Smart Communications and Joisto represents an exciting step forward for both companies and our customers.”
The acquisition comes alongside a period of sustained, rapid growth for Smart Communications, as the company has consolidated its leadership position in the cloud CCM (Customer Communications Management) and IXM (Interaction Experience Management) sectors and earned recognition for its strength among today’s leading healthcare, financial services, insurance, and government organizations. In addition, analyst firms including IDC, Aspire, Aragon, Datos, and Celent have once again ranked Smart Communications as a strategic leader and highlighted the company’s vision, cloud strategy, and product innovation.
As Smart Communications extends capabilities across the Conversation Cloud with this acquisition, the company will continue to integrate and partner with leading platform vendors worldwide to make ongoing customer conversations – and archival – seamless for the enterprises we serve.
About Smart Communications
Smart Communications provides the platform that leading organizations trust to deliver personalized, consistent, and compliant conversations across all touchpoints and channels. The Conversation Cloud™ consists of SmartCOMM™, for enterprise-scale customer communications, SmartIQ™ for digital forms transformation, and SmartDX™ for trade documentation. Over 650 enterprise organizations across the globe rely on Smart Communications to simplify and automate complex processes and deliver highly secure, frictionless experiences across the customer lifecycle. To learn more, visit smartcommunications.com
About Joisto
Headquartered in Helsinki, Finland, Joisto is a leading provider of pure cloud data archival and management solutions. Over 700 end customers make use of Joisto’s solutions to store, manage and retrieve their digital records and documents, ensuring that they meet regulatory requirements specific to their industry and geography. The Joisto platform leverages a modern, multi-tenant, SaaS architecture to ensure rapid scalability to meet the proliferating archival needs of customers, whilst meeting the archival compliance certification ISO146412. To learn more, visit joisto.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424187723/en/
Contacts
Media Contact
Smartcommunications@rlyl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Legora Attracts $80 Million Series B Funding as Top Global Law Firms and Legal Teams Rush to Adopt Its Collaborative AI21.5.2025 10:00:00 CEST | Press Release
Today, Legora announces an $80 million funding round led by ICONIQ and General Catalyst, with continued support from existing investors Redpoint Ventures, Benchmark, and Y Combinator. This latest round is a strong endorsement of Legora’s product quality, velocity and the remarkable traction it has achieved globally—underscored by its rapid progression from inception to Series B in under two years. The deal comes as adoption of legal AI surges across the world. Legora is at the forefront of this shift - with lawyers across 250 firms and legal teams in 20 markets globally making daily use of its platform to review and research with precision, draft smarter, and collaborate seamlessly. Legora operates out of New York, London, and Stockholm, with 100 employees drawn from some of the world’s leading global law firms and tech companies. Max Junestrand, CEO and founder of Legora said: “The investment is a clear validation of the value our product is delivering to lawyers around the world. Whi
SEKISUI CHEMICAL: Victory in German Patent Infringement Lawsuit Concerning PVB Interlayer Films21.5.2025 10:00:00 CEST | Press Release
The High Performance Plastics Company (President : Akira Asano) of SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Keita Kato; hereinafter “SEKISUI CHEMICAL”) hereby notifies that it has obtained judgments in its favor (hereinafter referred to as “the Judgments”) from the District Court Munich I on April 17, 2025, in the patent infringement litigation (docket No. 7 O 12401/24 and 7 O 12476/24) against Kuraray Europe GmbH (hereinafter referred to as “Kuraray Europe”), a subsidiary of Kuraray Co., Ltd which we previously announced in the press release dated October 16, 2024, titled “Filing of Lawsuit Seeking Injunction and Damages for Patent Infringement in Relation to PVB Interlayer in Germany.” This judgments found that the sound-insulating wedge products manufactured and sold by Kuraray Europe, namely “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” (hereinafter collectively referred to as “Kuraray Products”) infringe European Patent No.
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press Release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press Release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press Release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom